The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

Table 1

Baseline characteristics of participants.

Variable	ALA group ()	Placebo group ()	value
Age (year)^a	52.66 (4.81)	53.34 (4.45)	0.53
Female/male^b	20 (57.1)/15 (42.9)	19 (54.3)/16 (45.7)	0.81
Menopause ^b	13 (37.1)	14 (40)	0.81
Duration of diabetes (year)^a	3.65 (1.67)	3.57 (1.83)	0.83
HbA1C^a	6.6 (0.38)	6.7 (0.21)	0.17
BMI^a	25.4 (1.25)	24.93 (1.26)	0.11
Medication^b
Metformin	32 (91.4)	31 (88.6)	0.69
Sulfonylurea	8 (22.9)	10 (28.6)	0.58
ARB	28 (80)	27 (77.1)	0.77
ACEI	4 (11.4)	5(14.3)	0.72
Statins	29 (82.9)	30 (85.7)	0.74
Aspirin	29 (82.9)	27 (77.1)	0.55
Physical activity level^b
Low	20 (57.1)	21 (60)	0.80
Moderate	15 (42.9)	14 (40)

^aPresented as mean (SD), values are resulted from independent sample t-test. ^bPresented as number (%), values are resulted from a chi-square test. Low physical activity: score less than 600 MET-minutes/week and moderate physical activity: score between 600 and 3000 MET-minutes/week.